The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor.

Shaun Jordan, Vuk Koprivica, Ruoyan Chen, Katsura Tottori, Tetsuro Kikuchi, C Anthony Altar

Neuroscience Department, Maryland Research Laboratories, Otsuka Maryland Research Institute, 9900 Medical Center Drive, Rockville, MD 20850, USA. shaunj@otsuka.com

European journal of pharmacology 2002 Apr 26

filter terms:

Aripiprazole, 7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy]-3,4-dihydro-2(1H)-quinolinone, a novel antipsychotic with partial agonist activity at dopamine D2 receptors, bound with high affinity to recombinant human 5-HT(1A) receptors (h5-HT(1A)) in Chinese hamster ovary cell membranes and displayed potent, partial agonism at 5-HT(1A) receptors in a guanosine-5'-O-(3-[(35)S]thio)-triphosphate ([(35)S]GTP gamma S)-binding assay that was blocked completely by a selective 5-HT(1A) receptor antagonist. An interaction with 5-HT(1A) receptors may contribute to the overall efficacy of aripiprazole against symptoms of schizophrenia, including anxiety, depression, cognitive and negative symptoms, and to its favorable side-effect profile. Combined with previous studies demonstrating the potent partial agonism of aripiprazole at dopamine D2 receptors, this study suggests aripiprazole is the first dopamine-serotonin system stabilizer.

Citation

Shaun Jordan, Vuk Koprivica, Ruoyan Chen, Katsura Tottori, Tetsuro Kikuchi, C Anthony Altar. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. European journal of pharmacology. 2002 Apr 26;441(3):137-40